{"type": "root", "children": [{"type": "p", "children": [{"type": "t", "text": "\n In a study of diabetic nephropathy (DN) (see"}, {"type": "fg", "children": [{"type": "fg_f", "ref": "1"}]}, {"type": "t", "text": ",\n researchers examined HK-2 cells stimulated with serum from DN mice that were\n treated either with phosphate-buffered saline (PBS) or with Jiawei Shuilu\n Erxiandan (JSE). RNA sequencing analyses identified the long non-coding RNA\n CLYBL‐AS2, with comparative evaluations revealing differential expression\n levels between serum from normal individuals and DN patients. These findings\n suggest that CLYBL‐AS2 may play a regulatory role in the pathogenesis of DN,\n implicating it as a potential biomarker or therapeutic target for managing\n end‐stage renal disease (ESRD) associated with diabetes.\n "}]}, {"type": "rg", "children": [{"type": "r", "ref": 1, "children": [{"type": "t", "text": "Shengyu Cai, Juan Liu, Qingyu Ma, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Coptis inhibited epithelial-mesenchymal transition and fibrogenesis of diabetic nephropathy through lncRNA CLYBL-AS2-miR-204-5p-SNAI1 axis."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "J Drug Target (2020)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1080/1061186X.2020.1759077"}], "href": "https://doi.org/10.1080/1061186X.2020.1759077"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "32310009"}], "href": "https://pubmed.ncbi.nlm.nih.gov/32310009"}]}]}]}